Denali Therapeutics Inc’s recently made public that its COFO and Secretary Schuth Alexander O. unloaded Company’s shares for reported $39884.0 on Aug 12 ’25. In the deal valued at $13.58 per share,2,937 shares were sold. As a result of this transaction, Schuth Alexander O. now holds 242,346 shares worth roughly $3.69 million.
Then, Ho Carole sold 2,937 shares, generating $39,884 in total proceeds. Upon selling the shares at $13.58, the Chief Medical Officer now owns 217,391 shares.
Before that, Ho Carole sold 806 shares. Denali Therapeutics Inc shares valued at $11,800 were divested by the Chief Medical Officer at a price of $14.64 per share. As a result of the transaction, Ho Carole now holds 216,585 shares, worth roughly $3.29 million.
Cantor Fitzgerald upgraded its Denali Therapeutics Inc [DNLI] rating to an Overweight from a a Neutral in a research note published recently. Deutsche Bank began covering DNLI with “Buy” recommendation on February 11, 2025. Robert W. Baird started covering the stock on January 07, 2025. It rated DNLI as “an Outperform”.
Price Performance Review of DNLI
On Tuesday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock jump 1.54% to $15.21. Over the last five days, the stock has gained 2.08%. Denali Therapeutics Inc shares have fallen nearly -40.91% since the year began. Nevertheless, the stocks have fallen -25.37% over the past one year.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on 2025-09-30, growing by 0.4 million shares to a total of 14.15 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 13.75 million shares. There was a rise of 2.85%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 03, 2025 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
